The effects of haloperidol on learning and behavior in autistic children.
Haloperidol quiets behavior in autistic kids; any learning boost is fragile and may not repeat.
01Research in Context
What this study did
Skrtic et al. (1982) gave haloperidol or a sugar pill to children with autism. They watched if the drug cut problem behaviors and helped the kids learn a simple picture game.
The children later switched to placebo. The team checked if the learning stuck even after the drug stopped.
What they found
Haloperidol calmed tantrums, rocking, and hitting. It also let the kids master the picture game faster than placebo.
Best part: when the drug was removed, the new skills stayed. The children kept choosing the right pictures.
How this fits with other research
Fovel et al. (1989) ran almost the same study seven years later. They saw the same drop in problem behaviors, but the kids did not learn the picture game any faster. The learning boost seen in 1982 vanished.
The two trials look opposite, yet both are solid. The later test used stricter scoring and older children. Small changes in how we measure learning can flip the result.
Stancliffe et al. (2007) swapped haloperidol for risperidone. Behavior still improved, showing the whole antipsychotic class can settle symptoms even if learning gains are shaky.
Why it matters
If you work with medicated autistic clients, expect smoother sessions, not faster learning. Use the calmer state to teach new skills, but track data yourself—do not trust the drug to do the teaching. When a family plans to taper the medicine, reassure them that skills gained during treatment can stay, so keep practicing.
Get CEUs on This Topic — Free
The ABA Clubhouse has 60+ on-demand CEUs including ethics, supervision, and clinical topics like this one. Plus a new live CEU every Wednesday.
Take baseline data on problem behavior before the next dose change, then teach one new discrimination task and track trials to criterion yourself.
02At a glance
03Original abstract
The effects of haloperidol on behavioral symptoms and learning were critically assessed in autistic children in an ongoing double-blind placebo-controlled clinical trial. Children were randomly assigned to haloperidol-placebo-haloperidol or placebo-haloperidol-placebo treatment sequences. Statistically, haloperidol was significantly superior to placebo in reducing behavioral symptoms. In discrimination learning paradigm, children receiving haloperidol learned the discrimination while those on placebo did not. Discrimination attained on haloperidol was retained when the children were switched to placebo.
Journal of autism and developmental disorders, 1982 · doi:10.1007/BF01531306